NBC Securities Inc. Buys Shares of 8,600 Twist Bioscience Co. (NASDAQ:TWST)

NBC Securities Inc. purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,600 shares of the company's stock, valued at approximately $337,000.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the period. ARK Investment Management LLC increased its holdings in Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after purchasing an additional 237,772 shares during the period. Thrivent Financial for Lutherans raised its position in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Twist Bioscience by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after buying an additional 6,908 shares during the period. Finally, First Light Asset Management LLC purchased a new position in shares of Twist Bioscience in the 4th quarter valued at about $56,984,000.

Twist Bioscience Stock Up 3.3%

Shares of Twist Bioscience stock traded up $1.09 during trading hours on Tuesday, hitting $34.45. The company had a trading volume of 1,273,889 shares, compared to its average volume of 979,164. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The company's 50-day moving average is $34.17 and its two-hundred day moving average is $41.84. The company has a market cap of $2.06 billion, a P/E ratio of -10.19 and a beta of 2.38. Twist Bioscience Co. has a twelve month low of $27.12 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Barclays dropped their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird reduced their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paula Green sold 1,101 shares of Twist Bioscience stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the transaction, the senior vice president now directly owns 129,380 shares in the company, valued at $4,871,157. The trade was a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,012 shares of company stock valued at $817,752 in the last three months. 3.01% of the stock is currently owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.